Bioventus Inc. (NYSE:BVS) Stock Holdings Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Bioventus Inc. (NYSE:BVS) by 100.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 117,496 shares of the company’s stock after buying an additional 58,954 shares during the period. Dimensional Fund Advisors LP’s holdings in Bioventus were worth $676,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. LSV Asset Management purchased a new stake in Bioventus during the first quarter valued at about $1,170,000. Panagora Asset Management Inc. acquired a new stake in shares of Bioventus in the second quarter worth $787,000. American Century Companies Inc. grew its stake in shares of Bioventus by 289.5% in the second quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock worth $973,000 after acquiring an additional 125,736 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Bioventus in the second quarter worth $647,000. Finally, Rhumbline Advisers lifted its position in Bioventus by 5,367.9% in the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after purchasing an additional 51,478 shares during the period. Institutional investors own 62.94% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BVS shares. Craig Hallum lifted their price target on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group lifted their price objective on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 13th.

Bioventus Trading Up 7.8 %

Shares of Bioventus stock opened at $12.13 on Monday. Bioventus Inc. has a 12-month low of $2.85 and a 12-month high of $12.41. The stock has a market cap of $982.17 million, a P/E ratio of -18.38 and a beta of 0.90. The company has a quick ratio of 0.96, a current ratio of 1.33 and a debt-to-equity ratio of 1.82. The business’s 50 day moving average is $10.11 and its 200-day moving average is $7.34.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The business had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. During the same period in the previous year, the firm earned $0.14 EPS. Equities research analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Insider Buying and Selling at Bioventus

In related news, Director John A. Bartholdson bought 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The shares were bought at an average cost of $8.55 per share, with a total value of $218,025.00. Following the acquisition, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Director John A. Bartholdson bought 25,500 shares of the company’s stock in a transaction on Monday, August 19th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John A. Bartholdson bought 80,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $8.55 per share, with a total value of $684,000.00. Following the completion of the transaction, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.